This white paper looks at why dose escalation and expansion studies require RTSM that can absorb movement, not simply support launch. It discusses how dose changes, cohort evolution, schedule variation, and patient movement quickly increase complexity, and explains why planning for likely change early leads to more controlled, efficient study execution.

Key takeaways:

• Learn why early-phase oncology studies demand RTSM designed for adaptation, not static execution.

• Understand how complexity starts to build as dose levels, formulations, schedules, cohorts, and patient pathways begin to interact.

• See why dose complexity is also a system design issue, with direct implications for validation effort, amendment handling, and operational burden.

• Explore the difference between controlled adaptability and loose design, and why flexibility works best when it stays disciplined.

• Take away a practical planning lens for deciding what should be built in early, what can be prepared for, and where simplicity is still the better choice.